COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE ACETATE TREATMENT COMPARED WITH CABACITAXEL IN DOMINICAN REPUBLIC, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER THAT HAVE FAILED TO CHEMOTHERAPY WITH DOCETAXEL

被引：0
|
作者：
Obando, C. A. [1 ]
Desanvicente-Celis, Z. [1 ]
Gonzalez, L. [2 ]
Muschett, D. [1 ]
Gonzalez, F. [1 ]
Goldberg, P. [1 ]
机构：
[1] Janssen, Panama City, Panama
[2] Janssen, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN121
引用
收藏
页码：A635 / A635
页数：1
相关论文
共 50 条
  • [41] Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
    Auchus, Richard J.
    Yu, Margaret K.
    Nguyen, Suzanne
    Mundle, Suneel D.
    ONCOLOGIST, 2014, 19 (12): : 1231 - 1240
  • [42] EFFECTIVENESS OF ABIRATERONE IN THE POST-DOCETAXEL SETTING ON THE SURVIVAL OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN QUEBEC
    Rocha, J.
    Aprikian, A.
    Vanhuyse, M.
    Cury, F.
    Hu, J.
    Prevost, N.
    Dragomir, A.
    VALUE IN HEALTH, 2017, 20 (05) : A92 - A92
  • [43] Effectiveness of abiraterone in the post-docetaxel setting on the survival of metastatic castration-resistant prostate cancer patients in quebec
    Hu, Jason
    Rocha, Joice
    Aprikian, Armen
    Vanhuyse, Marie
    Cury, Fabio
    Prevost, Noemie
    Dragomir, Alice
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 268 - 268
  • [44] Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer
    Vogiatzi, Paraskevi
    Claudio, Pier Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (07) : 1027 - 1030
  • [45] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [46] COST-EFFECTIVENESS OF OLAPARIB COMPARED TO RUCAPARIB FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN UNITED STATES
    Ghule, P.
    Kohli, M.
    Malone, D. C.
    Nelson, R. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S429
  • [47] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [48] COST-UTILITY ANALYSIS OF ABIRATERONE IN THE TREATMENT OF DOCETAXEL-REFRACTORY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER COMPARED TO BEST SUPPORTIVE CARE IN IRAN
    Taheri, S.
    Majd, Karimi Z.
    Yousefi, N.
    Peiravian, F.
    VALUE IN HEALTH, 2019, 22 : S477 - S477
  • [49] REANALYSIS OF COST-EFFECTIVENESS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN USING A JAPANESE CLAIM DATA SET
    Shibahara, H.
    Shiroiwa, T.
    Tange, C.
    Nakamura, K.
    Ozono, S.
    Shimozuma, K.
    VALUE IN HEALTH, 2014, 17 (03) : A85 - A86
  • [50] PHARMACOECONOMIC ANALYSIS OF ENZALUTAMIDE AND ABIRATERONE FOR TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Avxentyev, N. A.
    Frolov, M.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
12345